treprostinil prodrug transdermal (TRX-248) / Corsair Pharma, United Therapeutics Corporation - LARVOL DELTA

Back to the Future: A Daily Trepostinil Prodrug Transdermal System Delivers Systemic Treprostinil with Modest Skin Irritation (PHA 2026) - "Corsair’s lead product candidate, a once-daily treprostinil prodrug transdermal system, is designed to deliver an inert treprostinil prodrug (TRX-248) that permeates the skin, enters systemic circulation, and is rapidly converted to treprostinil by hepatic metabolism. The Corsair leadership team includes George Mahaffey, a former executive at Cotherix who contributed to the genesis of the REVEAL Registry, and Dr. Bobby Singh, a drug-delivery executive responsible for developing multiple successful transdermal products currently used by patients in the United States."

First-in-human

Pharmacokinetics and safety of a novel once-daily treprostinil prodrug transdermal system in humans (PHA 2026) - "Once-daily administration of the TRX-248 transdermal system achieved steady, clinically meaningful treprostinil exposure with favorable local and systemic tolerability. These Phase 1 findings support TRX- 248 transdermal system as a promising and more convenient alternative to existing treprostinil delivery methods, facilitating earlier use of this key therapeutic molecule in PAH. Figures/Images: PHA 2026 Conference: Abstracts Figure 1: Mean (± SD) Treprostinil Pharmacokinetic Profile in Humans following once-daily TRX-248 Transdermal System Application (N=7) Figure 2: Steady-state Pharmacokinetic comparison between once-daily TRX-248 Transdermal System and Remodulin® (Subcutaneous Treprostinil)."

Clinical • PK/PD data

Study to Evaluate the parameters of TRX-248 Transdermal System in Healthy Female Volunteers (ANZCTR) - P1 | N=9 | Not yet recruiting | Sponsor: Corsair Pharma, Inc.

New P1 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases